Targeting Vascular Dementia and patients with Pre-Alzheimers risk
Vascular dementia is a cognitive dysfunction caused by the lack of oxygen to the brain. Previously known as multi-infarct dementia, vascular dementia is characterized by the development of cognitive impairment in association with single or multiple areas of infarction and/or subcortical ischemia.
World-wide Vascular Dementia patients: 6 million in 2017 and will double every 20 years.
Pre-Alzheimer’s disease or mild cognitive impairment (MCI) is a condition in which persons have some measured loss of memory. The causes underlying MCI may include changes in brain blood flow and increased brain inflammation such as that occurring in patients with heart disease.
Because vascular dementia can result from insults to a variety of cortical or subcortical areas, the neuropsychological profile of patients with vascular dementia can be quite varied. To date the FDA has not approved any drugs specifically to treat changes in judgment, planning, memory and other thought processes caused by vascular dementia.
ProNeurogen drugs are designed to improve brain blood flow and decrease brain inflammation related to vascular dementia and in patients at risk for pre-Alzheimer's disease.